Secukinumab and concomitant antibiotic use in patients with moderate-to-severe hidradenitis suppurativa: Week 16 efficacy and safety results from the Phase 3 SUNSHINE and SUNRISE trials

被引：0
|
作者：
Kokolakis, Georgios [1 ,2 ,3 ]
Martorell, Antonio [4 ]
Kerdel, Francisco [5 ]
Bettoli, Vincenzo [6 ]
Giamarellos-Bourboulis, Evangelos J. [7 ]
Sinclair, Rodney [8 ]
Kasparek, Torben [9 ]
Li, Xianjun [10 ]
Martinez, Angela Llobet [9 ]
Uhlmann, Lorenz [9 ]
Muscianisi, Elisa [11 ]
机构：
[1] Charite Univ Med Berlin, Psoriasis Res & Treatment Ctr, Dept Dermatol Venereol & Allergol, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Hosp Manises, Dept Dermatol, Valencia, Spain
[5] Florida Acad Ctr Res & Educ, Coral Gables, FL USA
[6] Azienda Osped Univ Ferrara, Dept Oncol & Specialist Med, OU Dermatol, Ferrara, Italy
[7] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med 4, Athens, Greece
[8] Sinclair Dermatol, Melbourne, Vic, Australia
[9] Novartis Pharma AG, Basel, Switzerland
[10] Novartis Pharmaceut, Shanghai, Peoples R China
[11] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42981
引用
收藏
页码：AB85 / AB85
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials
    Sandborn, W. J.
    Sands, B. E.
    D'Haens, G.
    Vermeire, S.
    Schreiber, S.
    Danese, S.
    Panes, J.
    Feagan, B. G.
    Reinisch, W.
    Niezychowski, W.
    Friedman, G.
    Lawendy, N.
    Yu, D.
    Woodworth, D.
    Mukherjee, A.
    Healey, P.
    Zhang, H.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S15 - S15
  • [42] Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results
    Papp, Kim A.
    Menter, Martin A.
    Abe, Masatoshi
    Elewski, Boni E.
    Feldman, Steven R.
    Gottlieb, Alice G.
    Thaci, Diamant
    Luger, Thomas
    Tatulych, Svitlana
    Gupta, Pankaj
    Proulx, James
    Lan, Shu-Ping
    Wolk, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB66 - AB66
  • [43] Safety and efficacy of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial
    Herra, L. Escudero
    Kimball, A.
    Zouboulis, C. C.
    Armstrong, A. W.
    Korman, N. J.
    Crowley, J. J.
    Lynde, C.
    Belknap, K.
    Gu, Y.
    Williams, D. A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 34 - 34
  • [44] Safety and efficacy of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial
    Kimball, Alexa
    Zouboulis, Christos
    Armstrong, April
    Korman, Neil
    Crowley, Jeffrey
    Lynde, Charles
    Belknap, Kimberly
    Gu, Yihua
    Williams, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB60 - AB60
  • [45] Association between skin-related quality of life and race in patients with moderate-to-severe hidradenitis suppurativa: Analysis of two phase 3 clinical trials
    Midgette, Bria
    Strunk, Andrew
    Garg, Amit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (06) : 1247 - 1250
  • [46] Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies
    Alavi, Afsaneh
    Hamzavi, Iltefat
    Brown, Kurt
    Santos, Leandro L.
    Zhu, Zhaoyin
    Liu, Huiqing
    Howell, Michael D.
    Kirby, Joslyn S.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (05) : 803 - 813
  • [47] Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial
    Zhao, Yan
    Zhang, Litao
    Wu, Liming
    Yang, Bin
    Wang, Jinyan
    Li, Yumei
    Li, Jingyi
    Diao, Qingchun
    Sun, Qing
    Zhu, Xiaohong
    Man, Xiaoyong
    Wang, Lihua
    Li, Linfeng
    Feng, Yanyan
    Zeng, Huiming
    Cai, Tao
    Ren, Hong
    Lu, Jianyun
    Lu, Qianjin
    Tao, Xiaohua
    Xiao, Rong
    Ji, Chao
    Li, Fuqiu
    Zhang, Jianzhong
    ALLERGY, 2024,
  • [48] Pooled safety analysis from two phase III studies of secukinumab in paediatric patients with moderate-to-severe plaque psoriasis up to week 52
    Sticherling, M.
    Nikkels, A. F.
    Hamza, A. M.
    Kwong, P.
    Ortmann, C. -E.
    Papanastasiou, P.
    Forrer, P.
    Keefe, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E39 - E40
  • [49] Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study
    Zouboulis, Christos C.
    Okun, Martin M.
    Prens, Errol P.
    Gniadecki, Robert
    Foley, Peter A.
    Lynde, Charles
    Weisman, Jamie
    Gu, Yihua
    Williams, David A.
    Jemec, Gregor B. E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 60 - +
  • [50] Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial
    Blauvelt, A.
    Papp, K. A.
    Gooderham, M.
    Langley, R. G.
    Leonardi, C.
    Lacour, J. -P.
    Philipp, S.
    Tyring, S.
    Bukhalo, M.
    Wu, J. J.
    Bagel, J.
    Frankel, E. H.
    Pariser, D.
    Flack, M.
    Scherer, J.
    Geng, Z.
    Gu, Y.
    Camez, A.
    Thompson, E. H. Z.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E248 - E248
12345